cination program for infants was launched in Taiwan in July, 1984. Pregnant women were screened for serum HBsAg. Infants of highrisk mothers with positive HBeAg received HBIG within 24 h of birth in addition to vaccines. All infants received 3 doses (at 0, 1 and 6 months of age) of recombinant HBV vaccines. All of the vaccines and HBIG given to the infants were paid for by the government. HBV vaccination coverage rate is as high as 97% at present. Following the universal hepatitis B virus (HBV) vaccination program for infants in Taiwan 25 years ago, HBsAg sero-prevalence declined from about 10% to 0.6% in children under 15 years old in Taipei city during the past two decades. The sero-positive rates for HBsAg, anti-HBs, and anti-HBc were 1.2%, 50.5%, and 3.7%, respectively, in those born after the vaccination program (<20 years old) in 2004. The institution of universal HBV vaccination decreases the incidence of HCC in children. From 1981 to 1994, the incidence of HCChepatocellular carcinoma in children 6 to 9 years of age declined from 0.52/100,000 for those born between 1974 and 1984 to 0.13 for those born between 1984 and 1986 (P<0.001) in Taiwan. Later on, we extended the follow-up to 2000, the incidence of HCC per 100,000 children declined from 0.54 to 0.20 in those born before versus after the vaccination program. A positive maternal HBsAg status was found in 89% of the HB-sAg sero-positive subjects born after the vaccination program. In spite of the success of hepatitis B immunization, childhood HCC still failed to be completely eradicated by the universal vaccination program. This is evidenced by the very high HBsAg sero-positive rate in our HCC children (97%) and their mothers (96%). The prevalence and clinical significance of the mutations in the a determinant (amino acids 121-149) of HBsAg was not well elucidated, particularly in the post-vaccination era. The prevalence of a determinant mutants in HBV-DNA positive children was 7.8% (8/103) in 1984, significantly increased to 19.6% (10/51) in 1989, peaked at 28.1% (9/32) in 1994, and remained at 23.1% (3/13) in 1999; it was higher in those fully vaccinated compared with those not vaccinated (15/46 vs. 15/153; p<,0.001). However, the number of mutant infected children in each survey was stable. The other group of subjects who are susceptible to vaccine failure is the immune-compromized hosts. In conclusion, universal HBV vaccination provides long-term protection up to 20 years, and a universal booster is not indicated for the primary HBV vaccinees before adulthood. Mother-to-child transmission is the primary reason for vaccine failure and needs to be tackled in future vaccination programs. The emergence of escape mutant did not impose any increased risk of chronic infection at this moment. The development of new vaccines is expected to overcome the vaccine failure.
CS12-03 Hepatitis B Virus Genetic Variability and its Clinical Significance
Hong Tang *. Current studies have showed that mutations in the genome exert a substantial effect on the replication capacity of the virus. Immune and antiviral selection pressures result in vaccine/immunoglobulin escape mutants and antiviral resistant variants. Viruses encoding changes associated with antiviral resistance often have reduced replication in vitro, but the accumulation of additional compensatory mutations helps restore viral fitness. Additionally, in our study, we found that HBV genome variation occurred in the hepatocyte nuclear factor (HNF) 4 and/or HNF3 binding sites may significantly change the capacity of viral replication. The mechanisms determining the emergence of viral variants in response to immune selection may be important in considering possible therapeutic interventions designed to prevent their pathophysiological consequences. Viral variants containing two nucleotide substitutions (A1764T and G1766A) in the proximal nuclear hormone receptor binding site in the nucleocapsid promoter are very common variants identified from patients who have seroconversion from HBeAg to anti-HBe antibody status.
The results of our study indicate that replication of wild type and variant viruses can be differentially regulated by nuclear hormone receptors, and this may be important in the selection of specific viral variants as a result of an antiviral immune response Chronic HBV infection is a dynamic state involving interaction between the virus, the hepatocytes and the immune cells of the host. The role of continuing HBV replication in the hepatic necroinflammatory response leading to hepatocarcinogenesis has been showed. Several HBV mutant strains including mutations in precore, core promoter and deletion mutation in pre-S/S genes have been reported to be associated with the pathogenesis of progressive liver disease, including hepatitis flare, decompensation, liver cirrhosis and hepatocellular carcinoma (HCC). The goal of therapy in patients with chronic hepatitis B is rapid viral suppression and long-lasting maintenance of undetectable levels of serum HBVDNA. Nucleoside/nucleotide analogues rapidly are becoming the treatment of choice for patients with Chronic Hepatitis B. The major draw back of this treatment is the considerable risk of developing antiviral drug resistance associated with progressive disease, which occurs most frequently in lamivudine-treated patients,bu talso has been shown for other agents (eg,adefovir, telbivudine and entecavir) evaluated in long-term studies. Location of the major antiviral drug-resistant mutations associated with LMV,LdT,ADV,TDF,and ETV have been identified in recent years. Antiviral therapy should be modifed as soon as resistance is detected. Therefore, it is necessary to monitor the occurrence and development of HBV variations and the relationship between variability and clinical outcome dynamically. Enhancing the biological characteristics research of hepatitis B virus would help us further understand the effect of mutations on viral replication capacity, and better understand the roles of mutations in drug-resistance and disease prognosis.
CS12-04 Hepatitis B and Transfusion Medicine: Unexpected Donor Screening Events

F. Blaine Hollinger *. Baylor College of Medicine, Houston, TX, USA
It is well recognized that the transfusion of blood containing HBsAg is associated with the development of posttransfusion hepatitis B. This risk of acquiring an HBV infection underwent a dramatic reduction with the advent of HBsAg screening of blood donors in the 1970s in conjunction with the implementation of an all-volunteer donor population. Subsequent studies in the 1980s and 1990s implicated high-titered, anti-HBc positive blood that lacked HBsAg and anti-HBs, in the transmission of HBV. This prompted the addition of anti-HBc screening of blood donors in those countries where HBV is not endemic. Later, it was discovered that the units of blood from these anti-HBc reactive,
